



**SAI PRIMUS LIFE
BIOTECH LIMITED**

CRITERIA / POLICY OF MAKING PAYMENTS TO NON- EXECUTIVE DIRECTORS

 **+91 413 2966314**

 **md@splbiotech.com**
www.splbiotech.com
CIN No: U24304PY2017PL C008147
GST No. 34AAYCS3936L1ZJ

 **R.S No. 4/3, Plot No. 33,**
Kurumbapet Industrial Estate,
Villianur Commune,
Puducherry - 605 009.



**SAI PRIMUS LIFE
BIOTECH LIMITED**

1. REGULATORY PROVISIONS:

In terms of the requirement stated under Companies Act, 2013 read with related rules issued thereon and Regulation 17(6) of SEBI Listing (Obligation and Disclosure Requirements), Regulations, 2015, **Sai Primus Lifebiotech Limited** ("the Company") has formulated a policy document namely "**Criteria or Policy of making payments to Non- Executive Directors**" which will deal with the remuneration of the Non- Executive Directors.

Section 197 of the Companies Act, 2013 and Regulation 17(6) (b) of SEBI Listing (Obligation and Disclosure Requirements), Regulations, 2015, require the prior approval of shareholders of the Company if it exceeds the prescribed limits under the Act for making payment to its Non- Executive Directors.

2. SITTING FEES:

The Non-Executive Directors ("NEDs") (which expression includes Independent Directors) may receive remuneration by way of fees for attending meetings of Board or Committee thereof. However, the amount of such fees shall not exceed Rupees One lakh per meeting of the Board or Committee or such amount as may be prescribed by the Central Government from time to time. The Company, **Sai Primus Lifebiotech Limited** has formulated this policy in accordance with the Companies Act, 2013 (hereinafter referred to as "the Act") and Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (hereinafter referred to as "Listing Regulations").

3. COMMISSION:

Section 197 of the Act allows the Company to pay remuneration to its NEDs either by way of a monthly payment or at a specified percentage of the net profits of the Company or partly by one way and partly by the other. Further, the section also states that where the Company has either Managing Director or Whole-time Director or Manager, then a maximum of 1% of its net profits can be paid as remuneration to its NEDs. In case there is no managing director or whole-time director or manager, then a maximum of 3% of net profit can be paid. Thus, the basis of payment to the NEDs is the net profit of the Company.

4. CRITERIA FOR FEE AND COMMISSION:

Within the parameters prescribed by the Act, the quantum of sitting fees and commission will be recommended by the Nomination and Remuneration Committee ("NRC") and approved by the Board of Directors of the Company. Overall remuneration (sitting fees and commission) should be reasonable and commensurate with the responsibilities, time spent in Board and Committee meetings by the NEDs. The aggregate commission payable to all the NEDs will be recommended by the NRC to the Board based on Company's performance, profits, return to investors, shareholder value creation and such other qualitative parameters.

5. PROFESSIONAL FEES:

Under the Act, Section 197 allows the Company to pay remuneration to its NEDs for services rendered by any such Director if: a. The services rendered are of Professional nature; b. In the



+91 413 2966314



md@splbiotech.com

www.splbiotech.com

CIN No: U24304PY2017PLC008147

GST No. 34AAYCS3936L1ZJ



R.S No. 4/3, Plot No. 33,
Kurumbapet Industrial Estate,
Villianur Commune,
Puducherry - 605 009.



SAI PRIMUS LIFE
BIOTECH LIMITED

opinion of Nomination and Remuneration Committee the Director possess the requisite qualification for the practice of the profession. As per the provisions of Section 188 of the Act, the Audit Committee and the Board of Directors of the Company shall approve the Professional fees to be paid to Non- Executive Director(s), and with the approval of the Shareholders wherever required.

6. REIMBURSEMENT OF ACTUAL EXPENSES INCURRED:

The Non-Executive Directors are also entitled for reimbursement of expenses incurred for attending the Shareholders meetings, Board Meetings and Committee meetings thereof, induction and training (organised by the Company for Directors).

7. REFUND OF EXCESS REMUNERATION PAID:

If any Director draws or receives, directly or indirectly, by way of remuneration any such sums in excess of the prescribed limit or without approval required under Section 197, he shall refund such sums to the Company, within two years or such lesser period as may be allowed by the Company and until such sum is refunded, hold it in trust for the Company. The Company shall not waive the recovery of any sum refundable to it unless approved by the Company by Special Resolution within two years from the date the sum becomes refundable.

8. STOCK OPTIONS:


As per the Regulation 17 of the Listing Regulations, the shareholders' resolution shall specify the limits for the maximum number of stock options that can be granted to NEDs, in any financial year and in aggregate.

Provided that an independent director shall not be entitled to any stock option and may receive remuneration by way of fees and reimbursement of expenses for participation in meetings of the Board and other meetings and profit related commission as may be approved by the shareholders of the Company from time to time.

9. AMENDMENTS:

The Board shall be responsible for the administration, interpretation, application and review of this policy. The Board shall be empowered to bring about necessary changes to this policy, if required at any stage in compliance with the prevailing laws.

D.S. [Signature]



+91 413 2966314



md@splbiotech.com
www.splbiotech.com
CIN No: U24304PY2017PLC008147
GST No. 34AAYCS3936L1ZJ



R.S No. 4/3, Plot No. 33,
Kurumbapet Industrial Estate,
Villianur Commune,
Puducherry - 605 009.